RxDoctor Payments Data

Nikki Patel, MD

Allergy & Immunology · Round Rock, TXNPI 1801030135

Payments from drug & device makers

$5,248in general payments, 2019–2025

Across 235 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$877
  • AstraZeneca$707
  • Sanofi$681
  • GSK$573
  • Takeda Pharmaceuticals U.S.A., Inc.$344
  • Amgen$274
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,01696%
  • Education$2324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,248 in reported general payments places this provider in the 45th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Medicare billing

Part B allowed, 2024
$267,123
Medicare patients
190
Services billed
16,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,368
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,814
Breo ElliptaFluticasone/Vilanterol18$8,349
Epinephrine21$3,509
Ipratropium Bromide43$1,130
Azelastine Hcl21$571
Albuterol Sulfate HfaAlbuterol Sulfate12$194
Montelukast Sodium30$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$573$18,71631 claims
AstraZenecaBreztri Aerosphere$707$8,81414 claims
Hikma Pharmaceuticals USAEpinephrine$17$3,50921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 336 allergy & immunology providers in Texas.

Other allergy & immunology in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →